Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 97 |
| Active Pipeline (Recruiting Now) | 47 (29) |
| Completed vs Stopped Early | 34 / 16 (16.5%) |
| Median Closed Actual Enrollment | 49 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UT Southwestern Simmons Cancer Center | Dallas, TX | 84 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 2 |
| Vanderbilt University Medical Center | Nashville, TN | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05262270 | Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the University of Texas Southwestern Medical Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.